Earlier this year, the contract research organization (CRO) opened its first office in the US. As part of the expansion, two new team members joined the team, including Roy Ovel as chief commercial officer and Charles Denis Maher as vice president, business development (Americas).
With offices in 13 countries, Optimapharm is now set to open another office in Cambridge, UK. Additionally, the company has hired a new senior vice president of business development for Europe, EMEA, Israel, and emerging countries, Maxime Stevens.
Ovel said the UK remains a key country for performing clinical trials – and it is important for the CRO to have a presence in the region to further support its clients in the US and across Europe.
“Despite the issues with Brexit, there is still considerable demand for trials to be performed in the UK and we expect that the UK will continue to be a leading market for pharmaceuticals as well as a strong contributor to the clinical research community,” he told us.
“The company has opened its first office in the country, and it will be from this hub that we continue to expand our commercial and operational presence in the country to continue support our client’s needs in the region,” Ovel added.
The company also acquired MKS Research in January 2018 with plans to double its revenue and become the largest independent CRO in the Central and Eastern Europe (CEE) and South East Europe (SEE) regions.